| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
150,780,000 |
| Market
Cap: |
59.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3938 - $0.3938 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
51,839 |
| Total Sell Value |
$0 |
$0 |
$0 |
$9,588 |
| Total People Sold |
0 |
0 |
0 |
6 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sender Gary |
Chief Financial Officer |
• – – |
2019-08-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
22,604 |
|
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2019-08-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
14,969 |
|
- |
|
| Gelone Steven P. |
President and COO |
• – – |
2019-08-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,250 |
55,776 |
|
- |
|
| Schroeder Theodore R |
Chief Executive Officer |
• • – |
2019-07-25 |
4 |
A |
$0.00 |
$0 |
I/I |
6,748 |
67,489 |
|
- |
|
| Rowland Charles A Jr |
Director |
– • – |
2018-12-24 |
4 |
B |
$1.31 |
$69,430 |
D/D |
53,000 |
53,000 |
2.39 |
- |
|
| Talbot George Harrison |
Director |
– • – |
2018-07-31 |
4 |
B |
$2.75 |
$39,875 |
D/D |
14,500 |
47,640 |
2.39 |
- |
|
| Burgess Daniel D |
Director |
– • – |
2018-07-31 |
4 |
B |
$2.75 |
$99,000 |
D/D |
36,000 |
36,000 |
2.39 |
- |
|
| Gelone Steven P. |
Chief Scientific Officer |
• – – |
2018-06-23 |
4 |
B |
$3.82 |
$38,200 |
D/D |
10,000 |
22,740 |
2.74 |
- |
|
| Broom Colin Md |
CEO & Director |
• • – |
2018-06-22 |
4 |
B |
$3.72 |
$18,600 |
D/D |
5,000 |
102,151 |
2.81 |
- |
|
| Schranz Jennifer |
Chief Medical Officer |
• – – |
2018-06-22 |
4 |
B |
$3.73 |
$20,515 |
D/D |
5,500 |
5,500 |
2.74 |
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2018-05-23 |
4 |
B |
$4.60 |
$9,936 |
D/D |
2,160 |
3,719 |
2.74 |
- |
|
| Webster Stephen W |
Director |
– • – |
2018-05-23 |
4 |
B |
$4.59 |
$36,720 |
D/D |
8,000 |
8,000 |
2.39 |
- |
|
| Broom Colin Md |
CEO & Director |
• • – |
2018-05-23 |
4 |
B |
$4.60 |
$46,000 |
D/D |
10,000 |
97,151 |
2.81 |
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2018-05-23 |
4 |
B |
$4.57 |
$9,140 |
D/D |
2,000 |
6,200 |
2.74 |
- |
|
| Crotty Robert |
General Counsel & Secretary |
• – – |
2018-05-23 |
4 |
B |
$4.48 |
$44,800 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2017-11-29 |
4 |
B |
$6.29 |
$9,869 |
D/D |
1,569 |
1,569 |
2.74 |
- |
|
| Talbot George Harrison |
Director |
– • – |
2017-09-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,350 |
33,140 |
|
- |
|
| Broom Colin Md |
Chief Executive Officer |
• • – |
2017-09-22 |
4 |
B |
$8.35 |
$21,610 |
D/D |
2,588 |
87,151 |
2.81 |
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2017-09-22 |
4 |
B |
$8.21 |
$16,420 |
D/D |
2,000 |
4,200 |
2.74 |
- |
|
| Vivo Capital Viii, Llc |
10% Owner |
– – • |
2017-09-18 |
4 |
B |
$9.46 |
$497,889 |
I/I |
52,631 |
494,329 |
1.5 |
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-09-14 |
4 |
S |
$8.52 |
$29,224 |
D/D |
(3,429) |
2,334,128 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-09-13 |
4 |
S |
$8.54 |
$193,956 |
D/D |
(22,721) |
2,337,557 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-09-12 |
4 |
S |
$8.63 |
$90,236 |
D/D |
(10,458) |
2,360,278 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-08-31 |
4 |
S |
$9.50 |
$6,071 |
D/D |
(639) |
2,370,735 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2017-08-08 |
4 |
S |
$10.50 |
$21,137 |
D/D |
(2,013) |
2,371,374 |
|
- |
|
323 Records found
|
|
Page 11 of 13 |
|
|
